These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 18476673)

  • 1. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.
    Wulff H; Zhorov BS
    Chem Rev; 2008 May; 108(5):1744-73. PubMed ID: 18476673
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls.
    Humphries ES; Dart C
    J Biomol Screen; 2015 Oct; 20(9):1055-73. PubMed ID: 26303307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
    Wang J; Xiang M
    Pharmacotherapy; 2013 May; 33(5):515-28. PubMed ID: 23649812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 5. The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.
    Pérez-Verdaguer M; Capera J; Serrano-Novillo C; Estadella I; Sastre D; Felipe A
    Expert Opin Ther Targets; 2016; 20(5):577-91. PubMed ID: 26634786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of neuronal KCNQ channel modulators.
    Gribkoff VK
    Expert Opin Ther Targets; 2003 Dec; 7(6):737-48. PubMed ID: 14640909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.
    Jensen BS; Hertz M; Christophersen P; Madsen LS
    Expert Opin Ther Targets; 2002 Dec; 6(6):623-36. PubMed ID: 12472376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The voltage-gated potassium channel K
    Tajti G; Wai DCC; Panyi G; Norton RS
    Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure Activity Relationship of Venom Toxins Targeting Potassium Channels.
    Batool S; Noureen N; Kamal MA
    Curr Drug Metab; 2018; 19(8):714-720. PubMed ID: 29283069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium Channels: A Big Family, Many Different Targets, Great Pharmacological Opportunities.
    Martelli A
    Curr Med Chem; 2018; 25(23):2626. PubMed ID: 30014793
    [No Abstract]   [Full Text] [Related]  

  • 11. Potassium channels as therapeutic targets for autoimmune disorders.
    Wulff H; Beeton C; Chandy KG
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K(+) channels as therapeutic targets in oncology.
    Stühmer W; Pardo LA
    Future Med Chem; 2010 May; 2(5):745-55. PubMed ID: 21426201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.
    Hofer MJ; Campbell IL
    Br J Pharmacol; 2016 Feb; 173(4):716-28. PubMed ID: 25917268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017).
    Vyas VK; Parikh P; Ramani J; Ghate M
    Curr Med Chem; 2019; 26(12):2062-2084. PubMed ID: 29714134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential therapeutic role of potassium channel modulators in asthma and chronic obstructive pulmonary disease.
    Malerba M; Radaeli A; Mancuso S; Polosa R
    J Biol Regul Homeost Agents; 2010; 24(2):123-30. PubMed ID: 20487625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminopiridines in the treatment of multiple sclerosis and other neurological disorders.
    De Giglio L; Cortese F; Pennisi EM
    Neurodegener Dis Manag; 2020 Dec; 10(6):409-423. PubMed ID: 33054615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.
    Maljevic S; Lerche H
    J Neurol; 2013 Sep; 260(9):2201-11. PubMed ID: 23142946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP sensitive potassium channels: potential drug targets in neuropsychopharmacology.
    Gehlert DR; Robertson DW
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1093-102. PubMed ID: 7846282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of aminopyridines in neurological disorders.
    Sedehizadeh S; Keogh M; Maddison P
    Clin Neuropharmacol; 2012; 35(4):191-200. PubMed ID: 22805230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
    Beeton C; Pennington MW; Norton RS
    Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.